Novo partners with Anthropic on Claude Science platform, shares up 3.55%
Novo Nordisk announced a strategic collaboration with Anthropic to use the Claude Science platform for accelerating pharmaceutical research and development. The partnership was disclosed alongside a 3.55% rise in Novo’s (NVO) share price, while rivals Eli Lilly (LLY) and Merck (MRK) also posted gains. CEO Mike Doustdar said artificial intelligence could "compress the path from research to…
Key points
- Novo (NVO) shares rose 3.55% after announcing collaboration with Anthropic to use Claude Science for drug development.
- EMA advisory committee gave a positive recommendation for Frehemgo, Novo’s hemophilia A therapy, slated for a Q4 2026 European launch.
- Neither company disclosed financial terms; the deal follows prior AI partnerships with OpenAI and AWS, though no AI‑discovered drug has regulatory clearance yet.
The European Medicines Agency’s advisory committee issued a positive recommendation for Frehemgo, Novo’s injectable hemophilia A therapy, covering adult and pediatric patients with or without inhibitors. Novo plans a limited European market launch in Q4 2026, followed by a broader EU rollout in early 2027. Clinical data from the FRONTIER trial showed lower annualized bleeding rates versus conventional clotting‑factor treatments, and the drug will be delivered in a prefilled, single‑use pen with flexible weekly to monthly dosing. To date, no AI‑discovered drug has achieved regulatory clearance, and Novo’s shares have fallen about 20% over the past year amid competition in the GLP‑1 weight‑loss market.
Novo Nordisk (NVO) Stock Surges 4% on Anthropic AI Collaboration and European Drug Approval
blockonomi.com · 18 September 2026
Loading the full article…
This text was published by blockonomi.com and written by Trader Edge. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Business & Funding
All →- Instinct reportedly in talks to raise at $10 billion valuation · 1 src
- ByteDance accounted for nearly 75% of Nscale's 2025 sales and used its Norway facility for Nvidia chips · 1 src
- Salesforce CEO Marc Benioff says Microsoft shut him out of OpenAI, bet on Anthropic · 2 src
- Go.AI raises $85 million Series A led by Updata Partners · 1 src
- Oppenheimer says Microsoft Azure and M365 can sustain acceleration in fiscal 2027 · 2 src
Comments
via GitHub Discussions